Have a personal or library account? Click to login
High Expression of CIP2A Can Promote the Proliferation, Migration, and Epithelial-Mesenchymal Transition of Diffuse Large B-Cell Lymphoma Cells Cover

High Expression of CIP2A Can Promote the Proliferation, Migration, and Epithelial-Mesenchymal Transition of Diffuse Large B-Cell Lymphoma Cells

Archivum Immunologiae et Therapiae Experimentalis
Volume 73 (2025): Issue 1 (January 2025)
By: Caifang Zhao,  Xiang Weng,  Wei He and  Yanming Lei  
Open Access
|May 2025

Figures & Tables

Fig 1.

CIP2A exhibited higher expression in DLBC. (A) The expression of CIP2A was verified in normal tissues or DLBC tissues from GEPIA online database. (B) The protein expression of CIP2A was examined in normal tissues (n=10) and DLBC tissues (n=10) through western blot. (C) The protein expression of CIP2A was measured in normal human B lymphocyte (GM12878) and DLBC cell lines (SU-DHL-4, SU-DHL-6 and SU-DHL-10). *p<0.05, ***p<0.001.
CIP2A exhibited higher expression in DLBC. (A) The expression of CIP2A was verified in normal tissues or DLBC tissues from GEPIA online database. (B) The protein expression of CIP2A was examined in normal tissues (n=10) and DLBC tissues (n=10) through western blot. (C) The protein expression of CIP2A was measured in normal human B lymphocyte (GM12878) and DLBC cell lines (SU-DHL-4, SU-DHL-6 and SU-DHL-10). *p<0.05, ***p<0.001.

Fig 2.

Inhibition of CIP2A restrained cell growth and metastasis in DLBC. Groups were separated into the Control, shNC, and shCIP2A. (1A, B) The protein expression of CIP2A was determined through western blot. (1C) The cell survival was confirmed through CCK-8 assay. (1D) The cell proliferation was inspected through colony formation assay. (1E) The cell migration and invasion were measured through transwell assay. ***p < 0.001. (2A) The Ki67 protein expression was examined through IF assay. (2B, C) The cell cycle was evaluated through flow cytometry. ***p < 0.001. CIP2A, cancerous inhibitor of protein phosphatase 2A; DLBC, diffuse large B-cell lymphoma; shNC, short hairpin negative control.
Inhibition of CIP2A restrained cell growth and metastasis in DLBC. Groups were separated into the Control, shNC, and shCIP2A. (1A, B) The protein expression of CIP2A was determined through western blot. (1C) The cell survival was confirmed through CCK-8 assay. (1D) The cell proliferation was inspected through colony formation assay. (1E) The cell migration and invasion were measured through transwell assay. ***p < 0.001. (2A) The Ki67 protein expression was examined through IF assay. (2B, C) The cell cycle was evaluated through flow cytometry. ***p < 0.001. CIP2A, cancerous inhibitor of protein phosphatase 2A; DLBC, diffuse large B-cell lymphoma; shNC, short hairpin negative control.

Fig 3.

Knockdown of CIP2A repressed EMT progress in DLBC. Groups were separated into the Control, shNC, and shCIP2A. The protein expressions of E-cadherin, N-cadherin, and α-SMA were evaluated through western blot. ***p < 0.001. CIP2A, cancerous inhibitor of protein phosphatase 2A; DLBC, diffuse large B-cell lymphoma; EMT, epithelial-mesenchymal transition; shNC, short hairpin negative control.
Knockdown of CIP2A repressed EMT progress in DLBC. Groups were separated into the Control, shNC, and shCIP2A. The protein expressions of E-cadherin, N-cadherin, and α-SMA were evaluated through western blot. ***p < 0.001. CIP2A, cancerous inhibitor of protein phosphatase 2A; DLBC, diffuse large B-cell lymphoma; EMT, epithelial-mesenchymal transition; shNC, short hairpin negative control.

Fig 4.

Suppression of CIP2A retarded the Wnt/β-catenin pathway. Groups were separated into the Control, shNC, and shCIP2A. The protein expressions of β-catenin, c-Myc, and cyclin D1 were inspected through western blot. ***p < 0.001. CIP2A, cancerous inhibitor of protein phosphatase 2A; shNC, short hairpin negative control.
Suppression of CIP2A retarded the Wnt/β-catenin pathway. Groups were separated into the Control, shNC, and shCIP2A. The protein expressions of β-catenin, c-Myc, and cyclin D1 were inspected through western blot. ***p < 0.001. CIP2A, cancerous inhibitor of protein phosphatase 2A; shNC, short hairpin negative control.
DOI: https://doi.org/10.2478/aite-2025-0016 | Journal eISSN: 1661-4917
Journal RSS Feed
Language: English
Submitted on: Feb 7, 2025
Accepted on: Apr 7, 2025
Published on: May 29, 2025
Published by: Hirszfeld Institute of Immunology and Experimental Therapy
In partnership with: Paradigm Publishing Services
Publication frequency: 1 issue per year
Keywords:
CIP2A,
EMT process,
Wnt/β-catenin pathway,
Diffuse large B-cell lymphoma
Related subjects:
Medicine,
Basic medical science,
Biochemistry,
Immunology,
Clinical medicine,
Clinical medicine, other,
Clinical chemistry

© 2025 Caifang Zhao, Xiang Weng, Wei He, Yanming Lei, published by Hirszfeld Institute of Immunology and Experimental Therapy
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

Previous articleVolume 73 (2025): Issue 1 (January 2025)Next article